caplacizumab inn trade name cablivi bivalent singledomain antibody vhh designed treatment thrombotic thrombocytopenic purpura ttp drug developed ablynx august approved european union treatment adults experiencing episode acquired thrombotic thrombocytopenic purpura attp conjunction plasma exchange antivon willebrand factor humanized acts blocking platelet aggregation reduce organ injury due results phase ii titan trial common adverse effects include injection site reactions reported patients hercules titan february caplacizumabyhdp cablivi ablynx nv approved united states treatment adults acquired thrombotic thrombocytopenic purpura attp drug used combination plasma exchange immunosuppressive us food drug administration fda considers firstinclass monoclonal article stub help wikipedia expanding ithttpsenwikipediaorgwikicaplacizumab